Show simple item record

dc.contributor.authorNewton, G
dc.contributor.otherStewart, M
dc.coverage.spatialInternational
dc.date.accessioned2020-08-19T09:50:55Z
dc.date.issued2018-08-30
dc.identifierGB2018050475W
dc.identifierWO2018154315
dc.identifier.citation2018
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3985
dc.description.abstractThe invention provides compounds of formula (I) wherein R is −CH3 or −CH2CH3 and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful in the treatment of diseases or disorders mediated by IKKE, TBK1 and/or SIK2 mechanisms in a subject, for example cancer and inflammatory and tissue repair disorders. The invention also provides uses of the compounds of formula (I) and compositions containing them. (Formula (I))
dc.languageeng
dc.language.isoeng
dc.subjectKinase
dc.subjectInflammation
dc.subjectCancer
dc.title5-(PYRIMIDIN-4-YL)-2-(PYRROLIDIN-1-YL)NICOTINONITRILE COMPOUNDS AS IKKE, TBK1 AND/OR SIK2 KINASES INHIBITORS
dc.typePatent
rioxxterms.licenseref.startdate2018-08-30
rioxxterms.typeOther
pubs.filed-date2017-02-23
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 3
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 3
pubs.patent-statusPCT
pubs.publication-statusPublished
pubs.embargo.termsNot known
icr.researchteamMedicinal Chemistry 3
dc.contributor.icrauthorNewton, Gary


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record